Chapter
The Science of Microdosing Psychedelics feat. James Fadiman
08:48 - 22:42 (13:53)
James Fadiman discusses the difficulty in defining microdosing and the variation in doses consumed due to uncertainty about the concentration of mushrooms and LSD, and the potential benefits of pursuing synthetic 5-MeO-DMT as a therapeutic product. He also mentions the use of tiny doses of hallucinogens to treat asthma, and how it relates to the microdosing movement.
Clips
Microdosing is a poorly defined concept that people are starting to experiment with, and for good reasons; people are finding it effective for different purposes.
08:48 - 20:11 (11:23)
Summary
Microdosing is a poorly defined concept that people are starting to experiment with, and for good reasons; people are finding it effective for different purposes.
ChapterThe Science of Microdosing Psychedelics feat. James Fadiman
Episode#605: Hamilton Morris and Dr. Mark Plotkin — Exploring the History of Psychoactive Substances, Synthetic vs. Natural Options, Microdosing, 5-MeO-DMT, The “Drunken Monkey” Hypothesis, Timothy Leary’s Legacy, and More
PodcastThe Tim Ferriss Show
Psilocin, the active metabolite of psilocybin, is structurally closer to DMT than to 5-MeO DMT, making it a challenge for lawyers to differentiate between the two.
20:11 - 22:42 (02:30)
Summary
Psilocin, the active metabolite of psilocybin, is structurally closer to DMT than to 5-MeO DMT, making it a challenge for lawyers to differentiate between the two. The experience of losing consciousness and having a near-death experience is more commonly associated with DMT than psilocin or 5-MeO DMT.